JAMA Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 16, 2025
This Viewpoint describes the need for more studies on best timing dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Язык: Английский
Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 238 - 238
Опубликована: Фев. 12, 2025
Metabolic diseases like obesity and diabetes are on the rise, therapies with biomacromolecules (such as proteins, peptides, antibodies, oligonucleotides) play a crucial role in their treatment. However, these drugs traditionally injected. For patients chronic (e.g., metabolic diseases), long-term injections accompanied by inconvenience low compliance. Oral administration is preferred, but delivery of challenging due to gastrointestinal barriers. In this article, we introduce available biomacromolecule for treatment diseases. The barriers oral drug strategies overcome also explored. We then discuss alleviating defects, including glucose metabolism, lipid energy such insulin, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, fibroblast growth factor 21 analogues, peptide YY analogues.
Язык: Английский
Процитировано
0
Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown
Опубликована: Март 3, 2025
Язык: Английский
Процитировано
0
JAMA Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Март 19, 2025
Язык: Английский
Процитировано
0
Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown
Опубликована: Апрель 4, 2025
To estimate the impact of semaglutide 2.4 mg treatment on risk major adverse cardiovascular events (MACE) in adults with overweight/obesity United States based SELECT trial patients atherosclerotic disease. Using 2023 census projections and National Health Nutrition Examination Survey data, we developed Markov population-based predictive models for US meeting inclusion criteria and, separately, eligible its MACE reduction indication. The 10-year rate recurrent deaths was estimated Secondary Manifestations ARTerial disease 2 calculator effect as per hazard ratio. Of 6 164 019 criteria, 523 218 (40.9%) are to have ≥1 new next 10 years no additional intervention. Semaglutide may prevent 496 400 events, a 16% relative reduction. An 103 630 predicted over years, which 332 597 (any cause, reduction) could be avoided mg. Among 22 653 158 FDA label 42.7% experience MACE; 1 934 493 231 295 (16% both). Four individuals CV event without can potentially between half million up population eligibility. What is context purpose this research study? More than 7 overweight or obesity, increases heart medication used treat type diabetes obesity. A clinical study called found that reduces attack, stroke, death by 20% obesity done? Our how many people would meet participation SELECT, they might regular medical care addition care. We also still alive if were treated semaglutide. same information all Food Drug Administration (FDA) indication These estimations large survey adults. main results? criteria. these, 41% at least years. If mg, nearly 500 000 more 300 avoided. qualify according these prevented. originality relevance Treatment reduce existing disease, showing substantial real-world setting States. different analyses add about reducing
Язык: Английский
Процитировано
0
JAMA Cardiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 16, 2025
This Viewpoint describes the need for more studies on best timing dicontinuation of glucagon-like peptide-1 receptor agonists before pregnancy.
Язык: Английский
Процитировано
0